cdk4 (Proteintech)
Proteintech is a verified supplier 
96
Structured Review
Proteintech
cdk4
Cdk4, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 641 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cdk4/CDK4+Antibody/pmc12796606-192-36-38
Average 96 stars, based on 641 article reviews
Cdk4, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 641 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+cdk4/CDK4+Antibody/pmc12796606-192-36-38
Average 96 stars, based on 641 article reviews
cdk4 - by Bioz Stars,
2026-10
96/100 stars
Images
1) Product Images from "A promising magnesium-related alloy with metabolic reprogramming and antitumor effects in hepatocellular and pancreatic cancer"
Article Title: A promising magnesium-related alloy with metabolic reprogramming and antitumor effects in hepatocellular and pancreatic cancer
Journal: Bioactive Materials
doi: 10.1016/j.bioactmat.2025.12.039
Figure Legend Snippet: Metabolomic Analysis Reveals Mg and Al-Mg Induce Metabolic Reprogramming in Hepatocellular and Pancreatic Cancer Cells. (A) Metabolomic profiling of PANC-1, PANC-1-Mg, PANC-1-Al-Mg, Huh7, Huh7-Mg, and Huh7-Al-Mg groups using LC-MS identified 1824 metabolites. (B) PCA illustrating clustering among different cell groups. (C) Heatmap showing differential abundances of characteristic metabolites across cell groups. (D) K-means clustering analysis highlighting metabolic differences among the cell groups. (E) Venn diagram displaying common differential metabolites among treatment groups. (F) Volcano plots of differential metabolites following Mg or Al-Mg treatment. (G) KEGG pathway enrichment analysis of differential metabolites. (H) Enrichment distribution of differential metabolites in Huh7 or PANC-1 cells treated with Mg or Al-Mg. (I) Quantitative analysis of intracellular metabolites including L-glutamine, adenine, uridine, cytidine, and guanine by ELISA with Mg or Al-Mg exposure. (J) Western blot analysis of p21, CDK4, and PCNA expression in PANC-1 cells after Mg or Al-Mg exposure. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
Techniques Used: Liquid Chromatography with Mass Spectroscopy, Enzyme-linked Immunosorbent Assay, Western Blot, Expressing
Related Articles
SDS Page:Article Title: Restoration of RBM22 overcomes the transcriptional and epigenetic barriers of cardiomyocyte proliferation for heart regeneration. Article Snippet: Protein concentrations were AR TI CL E IN P RE SS determined using the BCA protein assay kit (Thermo Fisher Scientific, 23227). .. Proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes (Cytiva, 10600002), which were blocked with 5% non-fat dry milk for 1 h. Membranes were incubated overnight at 4°C with primary antibodies: anti-RBM22 (Proteintech, 22103-1-AP, 1: 1000), Incubation:Article Title: Restoration of RBM22 overcomes the transcriptional and epigenetic barriers of cardiomyocyte proliferation for heart regeneration. Article Snippet: Protein concentrations were AR TI CL E IN P RE SS determined using the BCA protein assay kit (Thermo Fisher Scientific, 23227). .. Proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes (Cytiva, 10600002), which were blocked with 5% non-fat dry milk for 1 h. Membranes were incubated overnight at 4°C with primary antibodies: anti-RBM22 (Proteintech, 22103-1-AP, 1: 1000), Article Title: TRIM25 degrades BRD7 protein stability through the ubiquitin proteasome pathway to promote breast cancer progression and paclitaxel resistance by activating YB1/Bcl-2 transcription axis Article Snippet: .. Sections were incubated with anti-BRD7 (Proteintech, Wuhan, China), anti-TRIM25 (Proteintech, Wuhan, China), anti-YB1 (Abways, Shanghai, China), anti-Bcl-2 (Proteintech, Wuhan, China), anti-p21 (CST, MA, USA), Article Title: SIGLEC15 modulates the immunosuppressive microenvironment and suppresses malignant phenotypes in triple-negative breast cancer Article Snippet: .. The PVDF membrane was blocked with 5% fat-free milk for 2 h at room temperature and then incubated with primary antibodies (anti-SIGLEC15 (1:1000; Proteintech), anti-ZEB1 (1:1000; Proteintech), anti-ZEB2 (1:1000; Proteintech), anti-N-cadherin (1:1000; Proteintech), anti-E-cadherin (1:1000; Proteintech), anti-Vimentin (1:1000; Covance), anti-Slug (1:1000; Abcam), anti-Snail1 (1:1000; Proteintech), anti-Snail2 (1:1000; Proteintech), anti-Cyclin D1 (1:1000; Proteintech), anti-Cyclin B1 (1:1000; Abcam), anti-Cyclin E1 (1:1000; Abcam), anti-E2F1 (1:1000; Abcam), Article Title: Discovery of an orally bioavailable pyridone-based BRD4 inhibitor with potent antitumor efficacy in colorectal cancer. Article Snippet: Colorectal cancer (CRC) remains a major clinical burden with limited durable responses.. Given reports implicating Bromodomain-containing protein 4 (BRD4) in CRC proliferation and therapy resistance, more potent BRD4-targeting agents with proven in-vivo activity are needed.. Through virtual screening followed by structureguided chemical modification, we identified H5 as a BRD4 inhibitor. Membrane:Article Title: SIGLEC15 modulates the immunosuppressive microenvironment and suppresses malignant phenotypes in triple-negative breast cancer Article Snippet: .. The PVDF membrane was blocked with 5% fat-free milk for 2 h at room temperature and then incubated with primary antibodies (anti-SIGLEC15 (1:1000; Proteintech), anti-ZEB1 (1:1000; Proteintech), anti-ZEB2 (1:1000; Proteintech), anti-N-cadherin (1:1000; Proteintech), anti-E-cadherin (1:1000; Proteintech), anti-Vimentin (1:1000; Covance), anti-Slug (1:1000; Abcam), anti-Snail1 (1:1000; Proteintech), anti-Snail2 (1:1000; Proteintech), anti-Cyclin D1 (1:1000; Proteintech), anti-Cyclin B1 (1:1000; Abcam), anti-Cyclin E1 (1:1000; Abcam), anti-E2F1 (1:1000; Abcam), Article Title: Discovery of an orally bioavailable pyridone-based BRD4 inhibitor with potent antitumor efficacy in colorectal cancer. Article Snippet: Colorectal cancer (CRC) remains a major clinical burden with limited durable responses.. Given reports implicating Bromodomain-containing protein 4 (BRD4) in CRC proliferation and therapy resistance, more potent BRD4-targeting agents with proven in-vivo activity are needed.. Through virtual screening followed by structureguided chemical modification, we identified H5 as a BRD4 inhibitor. other:Article Title: HDAC2 promotes malignant progression by the RBM47/NONO axis in medulloblastoma Article Snippet: Anti-CDK4 , |
